EMA offers free scientific advice for Covid-19 developers
The EMA on Friday said it will fully waive fees for scientific advice to drugmakers developing potential treatments or vaccines for the novel coronavirus disease (Covid-19).
The EMA typically charges fees ranging from €43,700-€87,600 ($48,430-$97,080) for scientific advice, though small- and medium-sized entities and orphan product developers are eligible for reduced fees.
The EMA says companies should contact it “as soon as possible with information about their proposed development” and provides a dedicated email for inquiries.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.